ALSTON & BIRD

Health Care ADVISORY

AUGUST 21, 2023

How Is Congress Trying to Regulate Private Equity in Health Care? by Jane Lucas, Scott Kummer, and Rob Stone

On July 26, 2023, the House Ways and Means Committee held a legislative markup of H.R. 4822, the Health Care Price Transparency Act of 2023, seeking to bring additional price transparency to the health care industry by requiring some entities to publish pricing and other information. During the hearing, a venture capital and private-equity-related disclosure amendment was filed by Bill Pascrell, a long-serving Democrat from New Jersey.

This amendment would require "any specified medical care provider" to file a tax return containing information not normally found on a tax return, including gross receipts received as reimbursement from federal health programs, insurers, or other receivables in connection with providing medical care. A specified medical care provider is a corporation or partnership that is enrolled in Medicare, Medicaid, or, per the text, "in the course of any trade or business which includes the provision of medical care, employs any individual who is so enrolled or certified." This definition will require some entities owned by venture capital and private equity to comply because they have employees who are enrolled in Medicare or Medicaid. However, in some states, lay corporations cannot directly own or operate providers due to state corporate practice of medicine restrictions. In these states, management services organizations are often used, and it is not clear how these arrangements would be impacted because the language does not clearly contemplate such arrangements.

It would also require reporting information about locations, real estate that is owned or leased, adjusted taxable income, debt, sale of equity interests, and other financial and real-estate-related information of specified medical providers. The Secretary of the Treasury is given the authority to require reporting additional information, and the filed information would be made available to the public as soon as practicable. The failure to correctly file any single return could result in penalties of up to \$1 million.

During consideration of this amendment, the sponsor commented that the "octopus tentacles of private equity" have caused health care prices to increase and resulted in staff layoffs, particularly in nursing homes. He asserts that transparency is necessary to help prevent increasing health care costs. He expressed dismay that the provisions passed by the Energy and Commerce Committee are not in this markup. Bipartisan legislation from May 2023 from the House of Representatives' Energy and Commerce Committee creates a private equity reporting requirement to the Secretary of Health and Human Services, which is covered in <u>our earlier advisory</u>.

This advisory is published by Alston & Bird LLP to provide a summary of significant developments to our clients and friends. It is intended to be informational and does not constitute legal advice regarding any specific situation. This material may also be considered attorney advertising under court rules of certain jurisdictions.

After discussion, the amendment at the Ways and Means Committee was rejected on party lines. The debate about this amendment can be found starting at the 2:15 mark <u>here</u>, where the committee posts archived hearings.

While the amendment was defeated, the conversation about disclosure is certainly not over. It will resume in the fall after the August recess as the two sides seek to negotiate legislation about health care costs and transparency on the House floor. This legislative action is paralleled by scrutiny in the Senate. On June 1, the Senate Finance Committee held a hearing, "Consolidation and Corporate Ownership in Health Care: Trends and Impacts on Access, Quality, and Costs."

Congress returns to Washington in September, and the outlook for legislation affecting private equity is still not clear. While there is typically bipartisan agreement about increasing transparency in many facets of health care, legislative activity to date indicates there is generally disagreement between Republicans and Democrats about the role private equity should play in health care and whether it has an impact on health care costs.

Entities with ownership that could be affected by this legislation or similar legislation should continue to actively monitor its status and be prepared to address potential impacts to remain in compliance should Congress decide to require additional disclosures about ownership or revenue information.

You can subscribe to future *Health Care* advisories and other Alston & Bird publications by completing our **publications subscription form**. If you have any questions, or would like additional information, please contact one of the attorneys in our <u>Health Care Group</u>.

ALSTON & BIRD

WWW.ALSTON.COM

© ALSTON & BIRD LLP 2023

ATLANTA: One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia, USA, 30309-3424
404.881.7000
Fax: 404.881.7777
BEJJING: Hanwei Plaza West Wing
Suite 21B2
No. 7 Guanghua Road
Chaoyang District
Beijing, 100004 CN
+86.10.85927500
BRUSSELS: Rue Guimard 9 et Rue du Commerce 87
3rd Floor
1000 Brussels
Brussels, 1000, BE
+32.2.550.3700
Fax: +32.2.550.3719
CHARLOTTE: 1120 South Tryon Street
Suite 300
Charlotte, North Carolina, USA 28203-6818
+1704 444 1000
Fax: +1704 444 1111
DALLAS: Chase Tower
2200 Ross Avenue
Suite 2300
Dallas, Texas, USA, 75201
214.922.3400
Fax: 214.922.3899
FORT WORTH: Bank of America Tower
301 Commerce
Suite 3635
Fort Worth, Texas, USA, 76102
214.922.3400
Fax: 214.922.3409
LONDON: LDN:W
6 th Floor
3 Noble Street
London
EC2V 7DE
+44 20 8161 4000
LOS ANGELES: 333 South Hope Street
16th Floor
Los Angeles, California, USA, 90071-3004
213.576.1000
Fax: 213.576.1100
NEW YORK: 90 Park Avenue
15th Floor
New York, New York, USA, 10016-1387
212.210.9400
Fax: 212.210.9444
RALEIGH: 555 Fayetteville Street
Suite 2100
San Francisco, California, USA, 94105-0912
415.243.1000
Fax: 415.243.1001
SILICON VALLEY: 755 Page Mill Road
Building C - Suite 200
Palo Alto, California, USA, 9404-1012
650.838.2000
Fax: 202.239.333